Long-term side effects of adjuvant breast cancer treatment by Buijs, Ciska
  
 University of Groningen
Long-term side effects of adjuvant breast cancer treatment
Buijs, Ciska
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Buijs, C. (2008). Long-term side effects of adjuvant breast cancer treatment. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





Tamoxifen and uterine 
abnormalities 





Department of Medical Oncology1, Department of Gynaecologic Oncology2, Department of Pathology3 












J Clin Oncol 2004; 15: 2505-2507 
thesis_buijs_v15.3.pdf   121 10-12-2007   14:45:44





A 58-year-old postmenopausal woman was treated by a modified radical 
mastectomy for an estrogen and progesterone receptor-positive T1/N0/M0 
grade 2 ductal left breast cancer. She received adjuvant tamoxifen 20 mg daily. 
At the age of 60 years, she was referred with a 15-month history of vaginal 
bleeding, and a large pelvic mass. At gynaecologic examination, a central pelvic 
mass was present. Transvaginal ultrasound (TVU) revealed an enlarged uterus 
with markedly increased endometrial thickness of 7 to 8 cm, with a multicystic 
appearance. The ovaries seemed to be normal without ascites. Saline infusion 
sonography showed a large intrauterine polyp, as well as the multicystic pattern 
(Figure 1). Hysteroscopy indicated that this large polyp had a smooth surface 
(Figure 2). A biopsy of the polyp showed cystically dilated glands lined with 
flattened epithelium surrounded by dense, condensed stroma. The surface of 
the polyp was also lined with unilayered, atrophic epithelium (Figure 3). 
Figure 1. Increased thickness of multicystic endometrium and a large polyp (arrow). 
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Figure 2. Hysteroscopic view showing a large polyp with a smooth surface. 
 Figure 3. Histology of the biopsy: cystically dilated glands lined with flattened epithelium surrounded by dense, condensed stroma. 
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Because of peristent bleeding, a total abdominal hysterectomy with bilateral 
salpingo-oophorectomy was performed (Figure 4). 
This case demonstrates a large, benign endometrial polyp in a postmenopausal 
patient after 2 years of tamoxifen treatment. Since tamoxifen is widely used in 
breast cancer treatment, an increased incidence of endometrial hyperplasia, 
polyps, and two- to three-fold increased risk of endometrial adenocarcinoma 
and endometrial sarcoma have been described.1,2 TVU is a noninvasive method 
of screening for endometrial cancer; however, in postmenopausal tamoxifen 
treated women, TVU can give confounding ultrasound images.3 In as many as 
90% of postmenopausal tamoxifen users, TVU shows an increased irregular 
endometrial thickness suggestive of endometrial pathology.3,4 These tamoxifen-
induced sonographic findings, resembling Swiss cheese, are explained by the 
dense stroma and fluid-filled, dilated endometrial glands causing echolucent 
areas on ultrasound, which are mainly responsible for the enhanced endometrial 
thickness.3 Due to the high false-positive rate of TVU screening and the low 
incidence of malignancy, TVU screening in asymptomatic tamoxifen users is 
considered to be unwarranted,5 though there still is controversy on this issue. 
Figure 4. Opened uterus with a large, benign endometrial polyp. 
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Chapter 7.1
Tamoxifen-treated patients should be instructed and encouraged to report 
abnormal vaginal bleeding. Those who present with symptoms should have a 
hysteroscopy with endometrial sampling to exclude endometrial cancer or 
sarcoma, irrespective of the ultrasound findings. Physicians should be aware of 
the confounding effects of tamoxifen on the histological and ultrasonographic 
appearance of the endometrium. A multicystic endometrium or benign polyps, 
such as found in our patient, are typical for chronic tamoxifen users, and may 
confuse the unaware. 
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Tamoxifen, a non-steroidal anti-estrogen is the agent of choice in the treatment 
of premenopausal receptor positive breast cancer. We investigated the influence 
of tamoxifen on the endometrium and the menstrual cycle. 
Methods 
In tamoxifen-using breast cancer patients ≤55 years of age the last menstrual 
period was registered and the endometrial response measured by transvaginal 
ultrasonography (TVU) every 6 months. Premenopausal status was defined as 
serum levels of estradiol (E2) ≥0.10 nmol/L and follicle stimulating hormone 
(FSH) ≤30 IU/L. Patients with an endometrial response of >12 mm were offered 
an hysteroscopy and curettage. 
Results 
241 measurements were performed in 121 patients. Amenorrhea predicted 
menopausal status incorrectly in 85 of the 241 (35%) measurements in 47 
patients. In 8/47 premenopausal patients TVU showed an endometrial response 
of >12 mm (range15-29 mm). Histopathology in 6/8 women with an increased 
endometrial thickness showed no malignancy. No relation between E2 levels and 
endometrial response was found. 
Conclusion 
Tamoxifen leads to a disconnection between clinical and endocrinological 
menopause in breast cancer patients <55 years of age. In premenopausal 
patients tamoxifen has a predominantly anti-estrogenic effect on the 
endometrium without a correlation between E2 levels and endometrial response. 
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Tamoxifen is a non-steroidal anti-estrogen, which is used in the adjuvant 
setting and for metastatic disease in women with estrogen receptor positive 
breast cancer. Its inhibitory effect on breast cancer is caused by competitive 
inhibition of estrogen binding to its receptor. Tamoxifen however is not a pure 
estrogen antagonist. In various tissues tamoxifen also exhibits modest agonistic 
effects. In postmenopausal women tamoxifen has a mild estrogenic effect on the 
endometrium and is associated with endometrial hyperplasia and polyp 
formation. Tamoxifen increases the risk of endometrial carcinoma in breast 
cancer patients two- to threefold, but this is exclusively described in 
postmenopausal women.1-3 The absence of a reported increased risk of 
endometrial carcinoma in premenopausal women may be due to the fact that in 
the past premenopausal women received tamoxifen infrequently. Another 
reason might be that the effect of tamoxifen on the premenopausal 
endometrium in the presence of estradiol (E2) is different from the 
postmenopausal situation. Transvaginal ultrasonography (TVU) is a sensitive tool 
to diagnose endometrial abnormalities. In postmenopausal patients treated with 
tamoxifen the endometrial response as measured by TVU is increased, with 
characteristic sonographic changes referred to as a ”Swiss-cheese” aspect.4 
Relatively little attention has been paid to endometrial surveillance in 
premenopausal women. Since an increasing number of women are currently 
being treated with tamoxifen during their premenopausal years, the effects of 
tamoxifen on the premenopausal endometrium are of interest. Half of the 
premenopausal tamoxifen users will become oligo-, or amenorrhoeic.5 However, 
amenorrhoea in premenopausal tamoxifen users may be misinterpreted as post 
menopause. Determination of plasma E2 and follicular stimulating hormone 
(FSH) levels may be helpful to determine more precisely the menopausal status 
in tamoxifen users ≤55 years of age. Only a few studies about the effect of 
tamoxifen on endometrium have included premenopausal women.6,7 However 
these studies based menopausal status only on menstrual history and not on 
serum hormone levels. In the present study the influence of tamoxifen on the 
endometrial response and the menopausal status in breast cancer patients ≤55 
years of age was studied. 
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PATIENTS AND METHODS 
Between January 1995 and May 2000, tamoxifen-using breast cancer patients 
were referred to the gynaecology outpatient clinic for a gynaecologic screening 
program. Eligible were patients with no prior hysterectomy, ≤55 years of age and 
no evidence of breast cancer relapse. No patients in this group presented with 
gynaecological symptoms. Every six months, a gynaecologic and menstrual 
history was taken. Patients with an amenorrhea of >12 months were clinically 
considered as postmenopausal. Serum samples for determination of E2 and FSH 
were obtained at the same day of the gynaecological examination. For E2 
measurement a radio-immunoassay was used as described previously.8 Serum 
FSH levels were also determined by a radio-immunoassay (Amerlite FSH Assay, 
Johnson & Johnson Clinical Diagnostics Ltd, Amersham, UK). Serum E 2 levels of 
≥0.10 nmol/L in combination with FSH levels ≤30 IU/L were defined as 
premenopausal levels and E2 levels over 1.0 nmol/L were defined as 
supraphysiologic.9,10 
Duration and dose of tamoxifen was registered. Gynaecological screening 
included a pelvic examination and TVU, using an Aloka 620 sector scanner with 
a 5.0-MHz transvaginal transducer (Aloka, Tokyo, Japan). The measurement of 
the endometrial response was performed in the thickest part of the longitudinal 
plane. Normally, the endometrial response in premenopausal patients varies 
with the E2 levels during the menstrual cycle. Based on earlier studies we have 
defined a maximum endometrial response of equal or less than 12 mm as 
normal for premenopausal women.11-13 The endometrial response and the 
aspect of the endometrium were noted. Patients with an endometrial response of 
>12 mm were offered a hysteroscopy and curettage under local or general 
anesthesia. The existence of ovarian follicles was registered and ovarian cysts, 
defined as echolucencies with a diameter >3 cm, were measured (data published 
earlier).14 All examinations were performed by the same gynecologist (M.M.). 
IRB approval 
Clinicopathological, endocrinological and follow-up data were obtained during 
standard treatment and follow-up. For the present study all relevant data were 
entered into a separate, anonymous, password protected database. Protection of 
patient identity was guaranteed by assigning study-specific, unique patient 
numbers. Codes were only known to one dedicated data manager. Therefore, 
according to Dutch law, no further IRB approval was needed for this study. 
 




The agreement between menopausal status based on the definition of 
amenorrhoea of more/less that 1 year, respectively the definition based on 
serum hormone levels of both E2 and FSH was determined by Kappa. 
Separate associations of level of E2, level of FSH, age and duration of tamoxifen 
use with the thickness of the endometrium were studied using Spearman’s rank 
correlation. All the assessment points were used for these univariate analyses. 
Since using all the assessment points does not take into account that patients 
contributed unequal numbers of measurements, with different time intervals 
between these measurements, we performed a linear mixed-effect model (S-
Plus 6.0). Using this model we estimated the simultaneous effect of E2, FSH, age 
and duration of tamoxifen use on the thickness of the endometrium. P-values of 
<0.05 were considered significant and were tested two-sided. 
RESULTS 
Of all the tamoxifen using breast cancer patients, 121 patients were ≤ 55 years 
of age. A total of 241 examinations were performed in these 121 patients. The 
number of assessments ranged from 1 to 5 per patient. The number of pre- and 
postmenopausal examinations based on the clinical definition of last menstrual 
period or endocrinologal definition of serum hormone levels of E2 and FSH are 
shown in Table 1. 
 
Table 1. Numbers of assessments based on amenorrhoea and hormone serum levels. 
     
  Menopausal status based on amenorrhoea   
E2 and FSH levels  Premenopausal Postmenopausal Total 
Premenopausal  59 24 83 
Postmenopausal  61 97 158 
Total   120 121 241 
 
Amenorrhoea was unreliable in predicting endocrinological defined menopausal 
status. During 241 visits, amenorrhoea of ≥1 year was registered 121 times and 
amenorrhoea of <1 year was found 120 times. However, based on both E2 and 
FSH levels, only 83 of these measurements revealed an endocrinological 
premenopausal status and 158 measurements confirmed a postmenopausal 
status. The measure of agreement between clinical (amenorrhoea) and 
endocrinological diagnosis of menopausal status was low (Kappa =.294; P < 
.001). 
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In 8 patients, an increased endometrial response of >12 mm was observed (on 
11 measurements) while no significant correlation between E2 level and 
endometrial response was found. Six of these 11 TVUs with an endometrial 
response of >12 mm were performed in women with supraphysiological E2 
levels (>1.0 nmol/L). During 5 TVUs with an increased endometrial response of 
>12 mm women had physiological E2 levels of 0.1-1.0 nmol/L. 
Figure 1. Relation between serum E2 (nmol/L) and endometrial response (mm) of 83 measurements 
performed in 47 endocrinologically proven premenopausal patients, with or without the presence of 
ovarian cysts. The boundary between physiologic and supraphysiologic E2 (1.0 nmol/L) levels and the 
maximum value for endometrial response (12 mm) in premenopausal women are represented by the 
dotted lines. 
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Premenopausal serum levels in 47 patients during 83 visits were found. The 
mean age of these patients was 42 years (range 29-55 years) and the mean 
duration of tamoxifen use was 17 months (range 0.5-96 months). All patients 
used 40 mg tamoxifen daily. Of the 47 patients, 31 patients had received five 
cycles of FEC (5-fluorouracil (500 mg/m2), epirubicin (90 mg/m2), 
cyclophosphamide (500 mg/m2), 8 patients received four cycles of FEC followed 
by one cycle of high-dose chemotherapy (consisting of cylophosphamide 6 
g/m2, thiotepa 480 mg/m2 and carboplatin 1600 mg/m2 divided over four 
days), 6 patients received other regimes and 2 patients had received no 
chemotherapy before tamoxifen. None of the patients was given luteinising 
hormone-releasing hormone (LHRH) agonists. There was no significant 
correlation found between E2 levels and endometrial response in these 
endocrinologically proven premenopausal women (n=83, r=.138, P=.167) 
(Figure 1). 
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Figure 2. Relation between serum E2 (nmol/L) and FSH (U/L) of 83 measurements performed in 47 





















Supraphysiological E2 levels (>1.0 nmol/L) were detected in 22 of the 47 
patients (on 38 measurements). In the 47 endocrinological premenopausal 
women during 83 measurements, the mean E2 level was 2.29 nmol/L (n=47) in 
case of an ovarian cyst and 0.62 nmol/L (n=36) when no ovarian cyst was seen 
(P <.001). In 21/22 patients with an E2 level >1.0 nmol/L, ovarian cysts were 
observed by TVU. 
We found no significant association between FSH levels and endometrial 
response (n=83, r=-.144, P =.20). No significant association was found between 
duration of tamoxifen use and endometrial response (n=83, r=.096, P =.39). No 
significant association was found between age of the patient and endometrial 
response (n=83, r=.144, P =.20). We found no independent effect of E2 levels 
(B=.064, SE=.38, P =.87 ), FSH levels (B=-.13, SE=.10, P =.21), age (B=.17, 
SE=.13, P =.20,), or duration of tamoxifen use (B=.002, SE=.002, P =.35) on the 
endometrial thickness (using linear mixed effect models) (Figure 2). 
The characteristic sonographic “Swiss-cheese” aspect of the endometrium, often 
encountered in postmenopausal tamoxifen users, was not observed in any of the 
patients, also not in the patients with increased endometrial thickness.4 
Hysteroscopy and curettage were performed in 6 patients with thickened 
endometrium. Histological examination revealed several small benign polyps in 
one, inactive endometrium in three patients and benign proliferative 
endometrium in two other patients. Atypia or malignancy were not observed. 
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DISCUSSION 
This study shows that tamoxifen causes a disconnection between clinical and 
endocrinological menopause in young breast cancer patients. No correlation was 
observed between E2 levels and endometrial thickness. In only 5 of the 22 
patients with supraphysiologic E2 levels and in 5 of the 25 patients with normal 
premenopausal E2 levels an increased endometrial response was seen. 
In postmenopausal tamoxifen users an increased endometrial response has 
been described in up to 90% of the patients.4,15-20 In none of our 
endocrinological premenopausal patients the characteristic “Swiss cheese” 
aspect of the endometrium was found on TVU, as is often seen in 
postmenopausal tamoxifen users.4,21 Although not based on endocrinological 
confirmed premenopause, other studies did not report an increased endometrial 
response in premenopausal tamoxifen users either.6,7,22 A prospective study of 
symptomatic premenopausal breast cancer patients with abnormal vaginal 
bleeding either (n=34) or not using tamoxifen (n=25) showed no difference in 
mean endometrial response.6 In another study, no difference in endometrial 
response between tamoxifen-treated (n=21) and untreated (n=20) pre- and 
perimenopausal patients was found.7 A third small study reported high E2 levels 
and ovarian cysts in six premenopausal breast cancer patients on tamoxifen with 
a normal endometrial response.22 
In one out of six patients who underwent a curettage because of an endometrial 
thickness of >12 mm in our study, small endometrial polyps were found. 
McGonigle et al. did not find an increased incidence of polyps in premenopausal 
tamoxifen users in contrast to postmenopausal patients.23 In none of our 
patients hyperplasia, atypia or cancer of the endometrium was found. Although 
follow up is short, this is in line with another study, in which again no 
differences in endometrial histology between premenopausal tamoxifen treated 
(n=72) or untreated women (n=30) was reported.24 
In our endocrinological premenopausal tamoxifen users, E2 levels were not 
correlated with endometrial response. Apparently, tamoxifen exerts an anti-
estrogenic effect on the endometrium in the presence of E2, while it has pro-
estrogenic effects in postmenopausal women.25 About half of premenopausal 
women on tamoxifen report menstrual changes, including intermittent or lasting 
oligo- and amenorrhea.6,26,27 In our study as well, we observed that the 
menstrual history is unreliable to determine menopausal status during 
tamoxifen use. Therefore, during tamoxifen premenopausal status can only be 
determined endocrinologically by serum E2 and FSH levels. However, in none of 
the published studies investigating the influence of tamoxifen on the 
endometrium in premenopausal women, hormone serum levels were determined 
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to define premenopausal status.6,7,22 The present study is the first representing 
endometrial findings in endocrinologically proven premenopausal tamoxifen 
users. 
The gynaecological monitoring of postmenopausal women using tamoxifen is 
still a matter of debate. Based on the present study and scarce data in literature 
there is no evidence that tamoxifen increases the risk of endometrial carcinoma 
in premenopausal women. However, doctors should be aware of the 
disconnection between clinical and endocrinological menopause in young 
tamoxifen using breast cancer patients. Our data also show that half of the 
young tamoxifen users have hyperfunctioning multicystic ovaries producing high 
levels of E2.14 These high E2 levels may have an adverse effect on prognosis in 
estrogen receptor positive breast cancer patients, leading to impaired survival.28 
In premenopausal patients with metastatic disease, the combined use of 
tamoxifen with a LHRH analogue has shown superior results and is now an 
established therapy.29 This combination is also being evaluated and increasingly 
used in the adjuvant setting for premenopausal breast cancer patients. It is 
however as yet unclear if the endometrium of these young women with LHRH-
induced menopause will react in a similar way as in postmenopausal women on 
tamoxifen and whether this will result in enhanced endometrial cancer 
development. Amenorrhoea may lead to an erroneous interpretation of 
menopausal status in young tamoxifen using breast cancer patients. In 
premenopausal patients tamoxifen has a predominantly anti-estrogenic effect, 
even in case of supraphysiologic serum E2 levels. Tamoxifen leads to an 
endocrinological imbalance, as no correlation between E2 (or FSH) levels and 
endometrial response was found. 
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